Ready for Launch in Gastroesophageal Adenocarcinoma: Anti-HER2 Innovation in First-Line Management

Is your gastroesophageal adenocarcinoma (GEA) treatment plan ready for the latest human epidermal growth factor receptor 2 (HER2) innovations?

Credit available for this activity expires: 05/29/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/ready-launch-gastroesophageal-adenocarcinoma-anti-her2-2026a1000gtw?ecd=bdc_podcast_libsyn_mscpedu